3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Ovarian Neoplasms
14
Fallopian Tube Neoplasms
12
Breast Neoplasms
8
Prostatic Neoplasms
7
Neoplasms
7
Carcinoma, Ovarian Epithelial
6
Endometrial Neoplasms
5
Pancreatic Neoplasms
4
Uterine Cervical Neoplasms
3
Recurrence
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Solid Tumor
2
Small Cell Lung Carcinoma
2
Neoplasm Metastasis
2
Metastatic Castration Resistant Prostate Cancer
2
Lung Neoplasms
2
Leiomyosarcoma
2
Carcinoma, Transitional Cell
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Solid Tumor, Unspecified, Adult
1
Sarcoma
1
Prostate Cancer Metastatic
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Myeloproliferative Disorders
1
Interventions
Gemcitabine
25
Cisplatin
18
Carboplatin
10
Paclitaxel
9
Specimen Handling
6
Nivolumab
6
Doxorubicin
6
Docetaxel
6
pembrolizumab
5
Magnetic Resonance Spectroscopy
5
cabozantinib
4
avelumab
4
Vinblastine
4
Radiotherapy
4
Methotrexate
4
Fluorouracil
4
enfortumab vedotin
3
atezolizumab
3
aflibercept
3
Trastuzumab
3
Sunitinib
3
Ramucirumab
3
Platinum
3
Ipilimumab
3
Immunoglobulin G
3
Disulfides
3
CTLA-4 Antigen
3
Biopsy
3
1,2-diaminocyclohexaneplatinum II citrate
3
vinflunine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Urethral Neoplasms
×
rucaparib
×
Clear all
NCT03397394
2023-06-09
ATLAS
pharmaand GmbH
Phase 2
Terminated
97 enrolled
12 charts